Carderock Capital Management Inc. Has $6.06 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Carderock Capital Management Inc. raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,429 shares of the company’s stock after purchasing an additional 660 shares during the period. Carderock Capital Management Inc.’s holdings in IDEXX Laboratories were worth $6,059,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of IDXX. Geneos Wealth Management Inc. raised its holdings in IDEXX Laboratories by 34.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 325 shares of the company’s stock valued at $136,000 after acquiring an additional 83 shares during the period. Focus Partners Wealth increased its stake in shares of IDEXX Laboratories by 15.4% during the first quarter. Focus Partners Wealth now owns 46,831 shares of the company’s stock worth $19,667,000 after purchasing an additional 6,255 shares during the period. Glenview Trust co increased its stake in shares of IDEXX Laboratories by 105.6% during the first quarter. Glenview Trust co now owns 34,573 shares of the company’s stock worth $14,519,000 after purchasing an additional 17,761 shares during the period. Plato Investment Management Ltd lifted its holdings in IDEXX Laboratories by 37.1% during the 1st quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock worth $1,310,000 after purchasing an additional 835 shares during the last quarter. Finally, Bayforest Capital Ltd boosted its stake in IDEXX Laboratories by 77.1% in the 1st quarter. Bayforest Capital Ltd now owns 496 shares of the company’s stock valued at $208,000 after purchasing an additional 216 shares during the period. 87.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on IDXX. Leerink Partners increased their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an “overweight” rating in a research report on Friday, August 15th. Stifel Nicolaus set a $640.00 price objective on shares of IDEXX Laboratories in a research note on Monday, August 4th. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They set a “buy” rating and a $625.00 target price on the stock. Finally, Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, July 12th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $649.44.

IDEXX Laboratories Price Performance

IDXX stock opened at $637.95 on Thursday. The company’s 50-day moving average price is $599.72 and its two-hundred day moving average price is $510.79. The firm has a market cap of $51.04 billion, a P/E ratio of 53.12, a P/E/G ratio of 4.25 and a beta of 1.56. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.28 by $0.35. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the business posted $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 1,200 shares of IDEXX Laboratories stock in a transaction on Monday, August 11th. The stock was sold at an average price of $656.53, for a total value of $787,836.00. Following the transaction, the executive vice president owned 16,807 shares in the company, valued at approximately $11,034,299.71. This trade represents a 6.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 2,187 shares of the business’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director directly owned 262 shares of the company’s stock, valued at $169,600.46. This trade represents a 89.30% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,057 shares of company stock worth $34,293,468. 0.98% of the stock is owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.